Patents Assigned to The University
  • Publication number: 20230210987
    Abstract: The present invention is intended to provide an adjuvant having high safety to living bodies and an action to sufficiently reinforce immune function, and a vaccine comprising the adjuvant. Specifically, the present invention relates to 34 novel adjuvant candidate compounds, which have been identified by screening 145 food additives and 51 injection additives, using, as indicators, an increase in the antibody titer against influenza virus and a protective effect against infection with influenza virus, and then selecting those having the function of increasing the antiviral antibody titer in blood and the protective effect against viral infection. In addition, the present invention also relates to a vaccine comprising these adjuvant candidate compounds.
    Type: Application
    Filed: March 10, 2023
    Publication date: July 6, 2023
    Applicant: The University of Tokyo
    Inventors: Yoshihiro KAWAOKA, Huapeng FENG, Tokiko WATANABE, Makoto YAMASHITA
  • Publication number: 20230212306
    Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.
    Type: Application
    Filed: December 27, 2022
    Publication date: July 6, 2023
    Applicants: Daiichi Sankyo Company, Limited, The University of Tokyo
    Inventors: Kensuke Miyake, Yusuke Murakami, Yuji Motoi, Atsuo Kanno, Toshiyuki Shimizu, Umeharu Ohto, Takaichi Shimozato, Atsushi Manno, Takashi Kagari, Jun Ishiguro, Kensuke Nakamura, Takashi Isobe
  • Publication number: 20230212256
    Abstract: Provided herein are tumor-antigen VGLL 1 specific T cell receptors. The TCR may be utilized in various therapies, such as autologous cell transplantation, to treat a cancer. Methods for expanding a population of T cells that target VGLL 1 are also provided.
    Type: Application
    Filed: May 21, 2021
    Publication date: July 6, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: Gregory LIZÉE, Cassian YEE
  • Publication number: 20230211539
    Abstract: An object of the present invention is to provide a method for producing a polymeric molded product, the method enabling expansion of a temperature range that can be used for partial melting. The present invention provides a method for producing a polymeric molded product, which comprises subjecting a crystalline polyhydroxyalkanoate to a heating treatment at a temperature equal to or higher than a glass transition temperature; and melt-molding a polyhydroxyalkanoate yielded by the heating treatment, which comprises lamellar crystals that are different in lamellar thickness, in a temperature range where some of the lamellar crystals undergo melting and flowing, and the other balance lamellar crystals remain unmelted.
    Type: Application
    Filed: June 2, 2021
    Publication date: July 6, 2023
    Applicants: Mitsubishi Gas Chemical Company, Inc., The University of Tokyo
    Inventors: Akira MAEHARA, Tadahisa IWATA, Taku OMURA, Taizo KABE
  • Patent number: 11690825
    Abstract: The present invention concerns compounds and their use to treat cardiovascular disease, renal disease, thrombic disease, stroke, metabolic syndrome, cell proliferation, and ischemic cardiovascular disorders. Compounds of the present invention display significant potency as antagonists of 20-hydroxyeicosatetraenoic acid (20-HETE), and function as anti-hypertensive, anti-inflammatory, or anti-growth agents.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: July 4, 2023
    Assignees: Board of Regents, The University of Texas System, New York Medical College
    Inventors: John R. Falck, Michal L. Schwartzman, Victor Garcia
  • Patent number: 11690851
    Abstract: Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.
    Type: Grant
    Filed: April 17, 2021
    Date of Patent: July 4, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Thomas J. Slaga, Jacob Junco, Huiyun Liang, Sara Reyna
  • Patent number: 11690545
    Abstract: In one embodiment, a mixing device includes a sleeve that forms an inner space configured to receive a sample container, a housing associated with the sleeve, a mixing element contained within the housing that is configured to mix liquid contained within the sample container, and an activation element configured to activate the mixing element when the activation element is triggered.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: July 4, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventor: Christopher John Zahner
  • Patent number: 11693007
    Abstract: Provided herein are methods of detecting pancreatic cancer, particularly early stage pancreatic cancer, comprising measuring the expression of the biomarker panel TNC-FN III-C, TFPI, and CA19-9. The expression may be determined by an ELISA, such as a multiplex ELISA. Further provided herein are methods of treating subjects identified to have pancreatic cancer.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: July 4, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Ann McNeill Killary, Steven T. Lott, Nanyue Chen, Seetharaman Balasenthil
  • Patent number: 11691375
    Abstract: An object having a plurality of negative curvatures comprising a plurality of planar sections adjoined together by locking segments.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: July 4, 2023
    Assignee: Board Of Trustees Of The University Of Arkansas
    Inventors: Chaim Goodman-Strauss, Eugene Sargent
  • Patent number: 11690850
    Abstract: Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: July 4, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard T. Lewis, Matthew Hamilton, William J. Ray, Fernando Alvarez, Naphtali Reyna, Jason Cross, Suyambu Kesava Vijayan Ramaswamy
  • Patent number: 11692027
    Abstract: The present disclosure provides pharmaceutical compositions for monoclonal antibodies, antibody-related products, therapeutic proteins, peptides and other biopharmaceuticals. The compositions provide initial and long term stability of the biopharmaceutical agent, rendering them suitable for parenteral, pulmonary, transdermal, topical, intradermal, intrascleral, intracorneal, ocular and other forms of delivery. The compositions and methods lead to higher yields in dilute solutions and reduce unwanted aggregation of the biopharmaceutical agent. The compositions and methods also allow for disaggregation of previously aggregated proteins and protection from aggregation upon dilution. Additionally, provided are non-aggregating antibody reagents for analytical immunoassays including ELISA methods. The invention provides compositions and methods for topical, enteral, parenteral, pulmonary and other forms of delivery of biologically active substances.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: July 4, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Edward R. Kraft, Steven Andrew Giannos, Bernard Godley
  • Patent number: 11691995
    Abstract: The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: July 4, 2023
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Mark H. Schoenfisch, Jae Ho Shin, Nathan Stasko
  • Publication number: 20230203020
    Abstract: Small molecule disruptors of Beclin-1/Bcl-2 protein-protein interactions induce autophagy and hence are useful for treating a variety of indications where stimulation of autophagy is therapeutically useful, including cancer, infection immunity, neurodegeneration, longevity.
    Type: Application
    Filed: February 11, 2023
    Publication date: June 29, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: Jef De Brabander, Qiren Liang, Beth Levine, Wei-Chung Chiang
  • Publication number: 20230202858
    Abstract: A method of producing aluminum chlorohydrate comprises adding small form aluminum metal pellets to a reactant receiving space of a reactor tank to form a pellet bed; adding aqueous hydrochloric acid to the reactant receiving space of the reactor tank; and continuously circulating the aqueous hydrochloric acid through the pellet bed. In some embodiments, the continuously circulating aqueous hydrochloric acid dispels reaction gases from the pellet bed. Methods described herein can, in some cases, further comprise consecutively adding additional small form aluminum metal pellets to the reactant receiving space of the reactor tank as the small form aluminum metal pellets are consumed in the pellet bed.
    Type: Application
    Filed: February 20, 2023
    Publication date: June 29, 2023
    Applicants: C-KOE Mentals, L.P., Board of Regents, The University of Texas System
    Inventors: Chase McTaggart, Brian Hodges, Charles Koetting, Frederick M. MacDonnell, Brian Dennis, Mark Hulsizer
  • Publication number: 20230201235
    Abstract: Provided is a method of treating a disease caused by a nidovirus that encodes Nsp15, such as a coronavirus, an arterivirus, or a torovirus, in a subject in need thereof comprising administering a therapeutically effective amount of an active agent selected from 3?-uridylic acid, 5?-uridylic acid, citrate, methacycline, meclocycline sulfosalicylate, mitoxantrone, epirubicin hydrochloride, daunorubicin hydrochloride, sorafenib, sunitinib malate, primaquine diphosphate, closantel, isopropyl ester of N4-hydroxycytidine, GpU dinucleotide or derivatives thereof, and tipiracil or N-substituted derivatives thereof. Further provided are a method of inhibiting an Nsp15 endoribonuclease of a nidovirus that encodes Nsp15 and compounds of formulas (I?) and (II?).
    Type: Application
    Filed: March 11, 2021
    Publication date: June 29, 2023
    Applicants: The University of Chicago, UChicago Argonne, LLC, Auburn University
    Inventors: Youngchang Kim, Natalia Ivanovna Maltseva, Robert Jedrzejczak, Andrzej Joachimiak, Jacek Wower, Glenn Randall
  • Publication number: 20230203461
    Abstract: The present application relates to nucleic acids encoding polypeptides with ?-etherase activity; polypeptides with ?-etherase activity; vectors comprising said nucleic acids for the production of recombinant ?-etherase; cells, for example microbial cells transformed with nucleic acids encoding ?-etherase activity and vectors, including nucleic acids encoding ?-etherases; a composition comprising ?-etherases suitable for processing lignocellulose and a method that uses ?-etherases or compositions comprising ?-etherases in the processing of lignocellulose and related polysaccharides.
    Type: Application
    Filed: January 9, 2021
    Publication date: June 29, 2023
    Applicants: The University of York, Wisconsin Alumni Research Foundation
    Inventors: Neil Bruce, Nicola Oates, John Ralph
  • Patent number: 11684626
    Abstract: Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.
    Type: Grant
    Filed: April 17, 2021
    Date of Patent: June 27, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Thomas J. Slaga, Jacob Junco, Huiyun Liang, Sara Reyna
  • Patent number: 11684266
    Abstract: A probe comprising a body portion and a tip portion. The body portion comprises: a first mounting portion comprising a plurality of first carriers, each first carrier being arranged to support an elongate first waveguide, the first carriers being disposed in an equiangular arrangement around a longitudinal axis of the body portion; a plurality of first waveguides, each first waveguide being supported in a respective one of the plurality of first carriers; and a body end fitting at which first ends of the first waveguides are supported in the equiangular arrangement around the longitudinal axis of the body portion such that the first waveguides can transmit electromagnetic radiation signals from an energy source to the body end fitting and/or transmit electromagnetic radiation signals from the body end fitting to a receiver.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: June 27, 2023
    Assignees: The University of Bristol, The University of Exeter, Gloucestershire Hospitals NHS Foundation Trust
    Inventors: Nicholas Stone, John Charles Clifford Day
  • Patent number: 11684609
    Abstract: Provided, inter alia, are methods for treating an epilepsy disorder using clemizole, a clemizole analog, or pharmaceutical salts thereof.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: June 27, 2023
    Assignee: The Regents Of The University Of California
    Inventor: Scott C. Baraban
  • Patent number: 11684657
    Abstract: Provided herein are tumor-antigen VGLL1 specific peptides. Also provided herein are methods of generating VGLL1-specific T cells and their use for the treatment of cancer. In addition, the VGLL1-specific peptides may be used as a vaccine.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: June 27, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Gregory Lizée, Cassian Yee, Janos Roszik